Creso is riding a wave of easing regulations on cannabis as the company also unveiled plans to expand into Canada’s largest recreational market. As a result, the Canadian biotech company, a leader in COVID-19 therapies, has seen its share price soar 185 percent in the past year, with ARQ-531, which like ArQule, is on the same level as CG-806, up by more than 10 percent. In addition, news that pharmaceutical giant Merck would take over the company has doubled APS’s value in the last month and a half of this year.
All pharmaceutical stocks on the list had a cap, but the number of publicly-traded biotechnology companies in Canada with a market cap of at least $1 billion rose by 18%.
Although there are few domestic pharmaceutical stocks to choose from, owning these stocks can provide Canadians with income and diversification. Alternatively, you can buy shares in biotechnology companies traded on the Canadian stock exchanges.
It is also worth noting that Alexion has acquired and merged several companies since its inception, including Gilead Sciences (NASDAQ: GILD) and Merck & Co.
In 2009, Watson Pharmaceutical Inc., a top-selling generic drugmaker, acquired the Arnhem, N.J., facility called Pilar5 Pharma. Similarly, BMS sold its plant to Uman Pharma in 2008, and Pfizer sold it to Keata Pharma of Korea for $1.5 billion in 2009. Valeant has also tried to acquire Actavis and Cephalon, but the most significant acquisition was the $2.2 billion acquisition of the US drugmaker’s assets. This is only the latest in a long line of global MNEs to acquire the pipeline of Canadian biopharma SMEs and is one of their most significant acquisitions to date.
The company is better known as a manufacturer of Tylenol and Band-Aid but also has a large and profitable pharmaceutical division. The company, founded in Montevideo, Uruguay, in 1988, is an established pharmaceutical and medical device company developing medically registered and approved herbal cannabinoid products developed by Sandoz, one of the world’s largest manufacturers and distributors cannabinoids and other cannabinoids. In addition, Sandoz produces most injectable medicines used in Canada and a wide range of medical and surgical products.
Canadian Pharmaceutical Stocks
Overall, the Canadian pharmaceutical sector is the tenth-largest globally and accounts for 2 percent of the global market. Interestingly, Canada has the second-largest market share among the seven countries in global pharmaceuticals, behind the United States.
These companies are actively developing drugs to fight diseases, even coronavirus pandemics. Several biotech stocks are listed on the Toronto Stock Exchange (TSX Venture Exchange) and the Canadian Securities Exchange. These returns are possible because pharmaceutical companies develop products that people need, medicines that treat or prevent diseases such as cancer, diabetes, heart disease, Alzheimer’s, Parkinson’s and Alzheimer’s, and constantly invest in research and development to bring new medicines to market.
Canada has many pharmaceutical companies that have had great success in the past. Many of them can introduce new medicines for a wide range of diseases, including cancer, diabetes, heart disease, Parkinson’s and Alzheimer’s.
The Canadian pharmaceutical stocks listed below have been compiled using the TradingView stock screening device. This page provides a list of US-listed pharmaceutical ETFs tracked by the ETF Database. The following table shows all ETFs listed in the US pharmaceutical industry and currently tagged in our ETF database. There are now no pharmaceutical theses traded in the US, which we mark with “ETF” in our database, but there are a number of them.
Below, the Investing News Network has presented Canada’s top ten pharmaceutical stocks for their annual performance. Are you ready to see them in 2020 or even buy them?
Canadian companies Pfizer and GlaxoSmithKline, which are based among the top 10 largest companies, are the two companies that have experienced negative growth since 2011. At the same time as the patent cliff was being raised, two generic drug companies were among the top 10 companies for the first time in 2007. Under J. Michael Pearson’s leadership, Valeant has pursued buying other pharmaceutical companies that produce effective drugs for various medical problems and then raising the price of those drugs.
Creso capitalized on the shift by revealing that its Canadian subsidiary Mernova Medicinal has branched out into Ontario, Canada’s largest recreational cannabis market. Chief executive Brendan Kennedy noted that Canada had to act to export medicinal cannabis as biotech pharmaceutical product.
The Canadian pharmaceutical market alone is sufficient to support and justify the total development costs of a pharmaceutical product. However, clinical research in Canada generally accounts for only a tiny fraction of pharmaceutical products’ comprehensive research and development costs. For example, only 5% of Creso’s annual research budget is used for clinical research, less than half of it for medicinal cannabis.